Chris Degnan, Chief Financial Officer at UroGen Pharma, sold URGN on Oct 8, 2026
Data as of Oct 16
- Traded
- Oct 8, 2026
- Disclosed
- Oct 9, 2026
- Filed
- 1 day after the trade
Form 4s are due within two business days.
Official filing (SEC Form 4) ↗
The price around the disclosure
URGN since disclosure
−6.2%
after the sale
Similar stocks (XLV) since disclosure
+3.5%
XLV — its sector index fund
Change in closing price from Oct 9, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.
Our take
None of our tested rules fired on this trade.